Compare Quest Diagnostics Inc (DGX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs DENTSPLY SIRONA Inc — how do they compare? Quest Diagnostics Inc trades at $236.98 (market cap $26.21B), while DENTSPLY SIRONA Inc trades at $11.29 (market cap $2.31B). The key difference: Quest Diagnostics Inc is far larger — about 11.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| DGX | XRAY | |
|---|---|---|
Market Cap | $26.21B | $2.31B |
Sector | Health | Health |
52-Week High | $238.50 | $14.68 |
52-Week Low | $173.49 | $9.64 |
Enterprise Value | $31.97B | $4.39B |
Dividend Yield | 1.45% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
DENTSPLY SIRONA (XRAY) trades at $11.66, down 3.8% on the day, with a bearish technical outlook and mixed fundamentals. The stock faces headwinds from declining revenue and negative profitability, though Q2 2026 earnings beat expectations. Recent news highlights institutional stake increases and ongoing turnaround efforts amid weak dental market conditions.
The outlook remains challenging with persistent net losses and high debt, but cost controls and strategic partnerships offer potential stabilization. Risks include competitive pressures and macroeconomic softness, while analyst consensus is Hold with a $11.50 price target, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
